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Main text 
Brain tumors are highly heterogeneous neoplasms and show a marked variability in their 
biology and clinical presentation. Over the past decades brain tumor research has evolved 
and today is one of the most dynamic scientific areas in oncology. In this issue of Current 
Opinion in Neurology, some of the most innovative, but at the same time controversial 
issues in contemporary neurooncology will be discussed. The topics reviewed include recent 
advances in tissue-based classification of brain tumors, the emerging role of 
immunotherapies in brain tumors, the significance of chemotherapy for the treatment of 
low-grade gliomas and the potential value of tumor-treating fields as a novel treatment 
modality of glioblastoma. Although covering various aspects of neurooncology, one common 
denominator of these topics is that they are controversially debated in the international 
community and will likely continue to fuel ongoing discussions in the next years.  
The classification of tumors of the nervous system has so far been based on 
histopathological tumor appearance and the most commonly used classification system is 
regularly published and updated by the World Health Organization (WHO) [1].  However, 
insights from the last years have demonstrated that molecular information significantly 
contributes to better prognostication of the clinical course of some brain tumors than 
histology alone. For example, diffuse gliomas with or without mutation in one of the IDH 
genes have considerably different median overall survival times and molecular data such as 
the 1p/19q status strongly correlate with sensitivity to cytotoxic therapies. Drs. Peter 
Wesseling and Elisabeth Jane Rushing summarize current discussions focusing on how to 
incorporate these molecular markers into the classical histopathological diagnoses to 
provide a clear and clinically useful modern classification system for brain tumors.   
Low-grade gliomas are rare brain tumors and for decades the treatment of these tumors was 
limited by the lack of clinical trial data as a basis for evidence-based decision-making [2]. 
Recently however, data from adequately powered clinical studies performed over long 
periods of time and through effective international collaboration became available. The 
results obtained from these studies answered some questions, but gave raise to new 
questions as well as challenges and Dr. van den Bent will discuss the issues arising with 
regard to optimal selection and timing of chemotherapy for patients with low-grade gliomas.  
The treatment of glioblastoma is challenging and despite a wealth of pathobiological and 
clinical studies conducted over the past decades, the prognosis of glioblastoma patients is 
still dismal with overall survival times of approximately 15-17 months within clinical trials 
despite multimodal therapy [3]. Unfortunately, a number of rationally targeted therapeutic 
interventions such as drugs targeting specific molecular aberrations found in glioblastoma 
have not been successful. Therefore, there is a strong need to identify novel and effective 
treatment approaches for this devastating disease. Recent findings suggest that novel 
immunotherapeutic approaches such as advanced vaccination strategies or immune 
checkpoint modulators as well as the application of electromagnetic fields may provide 
some benefit for glioblastoma patients. The reviews by Drs. Weiss, Weller & Roth, 
Bienkowski & Preusser and Chamberlain & XXX in this issue of Current Opinion in Neurology 
aim at providing a balanced overview of the available data and the current controversies in 
these dynamic fields of research.   
We are confident that the topical reviews in this issue will help to catalyze the most relevant 
critical issues from the currently available evidence that need to be addressed by further 
studies. After all, only well-designed and strictly controlled investigations tailored to answer 
specific uncertainties will allow us to unequivocally answer open questions and make 
advances that truly benefit our patients. 
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